Prof Ziad Mallat leads Cambridge effort to win 30m to tackle leading cause of heart attacks and strokes – Cambridge Independent

It is the worlds biggest killer and yet we dont fully understand the leading cause behind it.

Cardiovascular diseases claimed an estimated 17.9 million lives in 2016 31 per cent of all deaths around the globe.

And 85 per cent of these were due to heart attacks and stroke, most commonly caused by a blockage of the arteries known as atherosclerosis.

Now an international team led by a Cambridge professor of cardiovascular medicine is competing for a 30million prize from the British Heart Foundation to unravel its secrets.

If they beat the other three shortlisted teams in the charitys Big Beat Challenge, they will create the worlds first 3D map of atherosclerosis at single cell resolution, giving unparalleled insight into this hardening or blocking of the arteries.

Prof Ziad Mallat, of the Department of Medicine at the University of Cambridge, tells the Cambridge Independent:We are excited about the prospect of this. We hope we have assembled the right team.

Atherosclerosis is very debilitating. If it happens in the arteries that supply the brain, it causes stroke. If it happens in the arteries supplying the heart, it causes heart attacks.

It is really common across the world. Every five minutes in the UK there is one heart attack and one stroke.

Why is this having such a huge impact on the quality of life of people? We believe something is not being treated or understood.

Clinicians currently treat the risk factors for the disease, which include high blood cholesterol, high blood pressure and diabetes.

What we dont do is really treat what causes the disease, which is the malfunctioning of the immune system, says Prof Mallat.

When you have high blood pressure or cholesterol, this injures the arteries. Initially, the immune system sends immune cells to the injured vessel to try to heal the artery.

However, what we know is that most of the time the immune system doesnt operate properly and this prevents the healing, and so the disease progresses.

We have good understanding of how this happens in pre-clinical models, like mouse models, but very limited understanding of how it happens in humans.

We think this is what is preventing doctors and scientists from finding a treatment that would transform the way patients are treated.

Through their iMap, as they are calling it, Prof Mallat and the team of global experts he has assembled want to understand what is happening in the accumulations, known as plaques, that block the arteries and affect blood flow to the heart and other parts of the body. The plaques can be made up of fat, cholesterol, calcium and other substances.

These plaques obstruct the lumen [the interior space in the artery] and even burst into the lumen, leading to clot formation, which obstructs the blood flow. This causes the heart attacks and strokes, says Prof Mallat.

Our idea is to build the first 3D map of these fatty plaques, at

. We would like to know what each immune cell and each cell in the vessel wall is doing. What is its genetic make-up? What is its protein make-up? What is the fuel that it is using? Why, when the immune cell comes along to do a good job, does it stop doing it?

We want to interrogate each cell and work out how it is interacting and communicating with other cells.

Only with this 3D map of the plaques will we be able to understand what is happening inside. Once we have done this, we will be able to harness this knowledge to find new protective methodologies and therapies.

These therapies could harness the immune system, which raises the possibility of vaccinating against atherosclerosis.

If we understand how the immune cells react, we can use the information to re-educate them with vaccination, suggests Prof Mallat. If they are overreacting to fat components or protein components, we can educate them to make them do the right job when they see this in the arteries, to reduce the inflammation and limit the development of the disease.

The scale of this challenge, however, is vast and requires a multi-disciplinary approach.

It needs a lot of different expertise around the world, says Prof Mallat. You need good cardiologists, good molecular biologists, immunologists, mathematicians and computer scientists because the information will be huge and needs to be integrated together. You need people who know a lot about genomics, lipidomics and proteomics, so we have gathered world-leading experts in each of these areas to come together and look at this problem from every angle possible.

Among those helping Prof Mallat is Sarah Teichmann, from the Wellcome Sanger Institute at Hinxton, who is the co-founder of the global consortium working on the Human Cell Atlas a hugely ambitious and important project creating comprehensive reference maps of all human cells in the human body.

They are looking at the make-up of healthy organs, notes Prof Mallat. Some of the investigators are mapping some of the arteries and are looking at vascular cells like endothelial cells. It is intriguing but nobody else is looking at other cells in the artery. We are looking at both the healthy arteries and the diseased arteries. It is building on the work of the Human Cell Atlas.

Also on the team are experts from Imperial College London, Germany, France, Spain, the La Jolla Institute of Immunology in San Diego and from Icahn School of Medicine at Mount Sinai in New York.

Key to their work is the need for data and samples, and the group has multiple sources available.

We have organ donors from the Cambridge bio-repository and the clinical school at Mount Sinai, so we have access to healthy and diseased arteries from the same individuals.

We have access to blood from these individuals and to immune cells from other parts of the body, so we can compare what the immune cells are doing in different compartments.

The other source is from a cohort of thousands of individuals, through a collaboration with Professor Valentin Fuster in Madrid, who have been followed for more than 10 years, and they will be followed for another 10 years.

We have blood samples and microbiota from them. We also have access to imaging of their arteries. They are followed for cardiovascular outcomes, so if someone has a heart attack or stroke, it is documented.

We will be able to look at the ageing of the immune system in these individuals and how this correlates to changes in their arteries and the occurrence of disease.

All of this is being done at very high resolution, which has not been done before. Integrating the information from the genes, the proteins, the lipids and so on, to have a broad view, has never been possible.

There are parallels with the work being carried out at Cancer Research UK Cambridge Institute under Prof Greg Hannon, where the first virtual 3D tumour is being created using a multi-disciplinary team.

We are discussing with him how we can integrate some of the technologies he is developing. It will be fantastic to collaborate with him on this, says Prof Mallat.

What is known already is that our arteries are sensitive to changes in blood flow.

Even subtle perturbations in the micro-environment are sensed by the arteries and can be considered as a danger, explains Prof Mallat.

When it interprets this as a danger, it sends signals to the immune system to react. I would say this is happening almost continuously, and is aggravated of course when you have additional stimuli like high blood cholesterol or exposure to smoke.

While the use of imaging and monitoring of biomarkers is helping us diagnose atherosclerosis earlier, Prof Mallat describes this as not optimal, because we dont understand the disease in a comprehensive manner. A 3D map would aid diagnosis, prediction and prevention of disease, as well as opening up new therapeutic avenues.

Nobody knew 10 or 15 years ago that the immune system could play such a huge role in cancer, Prof Mallat points out. Now cancer immunotherapy is advancing enormously. We are convinced that atherosclerosis is highly motivated by the immune system but no-one is targeting the immune system to treat it. Thats why we want to understand it and we think this could really induce a revolution in our understanding and how we treat it.

Cambridge Cardiovascular to host events at Cambridge Science Festival

Visitors to Cambridge Science Festival will have a chance to find out more about the iMap project and the work of cardiovascular researchers.

Cambridge Cardiovascular, an umbrella group for the field, is involved in organising activities once again at this years festival, which runs from March 9 to 22.

At 6-7pm on Wednesday, March 18 at the Mill Lane lecture rooms in Cambridge, a talk titled More than a blocked pipe: The hardening of the arteries and their role in stroke and heart attacks will be delivered by Dr Nick Evans, of the Department of Medicine, and Prof Melinda Duer, of the Department of Chemistry.

At 6-7pm on Friday, March 20, also at Mill Lane lecture rooms, Dr Sanjay Sinha, of Cambridge Stem Cell Instituteand the Department of Medicine will discuss Mending broken hearts: stem cells for heart disease.

Then, from 11am to 4pm on Sunday, March 22, A View of the Heart will be on offer at the Cambridge Academy for Science and Technology, in Long Road, where cardiovascular scientists will help you explore the organ and visualise heartbeats.

Book at sciencefestival.cam.ac.uk.

The Big Beat Challenge

The British Heart Foundations 30million Big Beat Challenge is designed as the charitys moon-shot to propel our understanding of cardiovascular disease into a new era.

Some 75 applications were received from 40 countries following its launch in August 2018, and these have been whittled down to four, including the one led by Prof Mallat to map and treat atherosclerosis. The other ideas are:

Hybrid heart

Led by Jolanda Kluin, professor of translational cardiothoracic surgery at the University of Amsterdam in the Netherlands, this team plans to create a solution for heart failure by developing a soft robotic heart. They intend to design, build, test and implant a hybrid heart that consists of a soft robotic shell forming the soft artificial muscles and sensors to enable natural motion, and a tissue-engineered lining to make sure all the surfaces in contact with blood are safe. With wireless energy transfer, the vision is that this could replace the need for human heart transplantation.

Echoes

Led by Professor Frank Rademakers, chief medical technology officer at University Hospitals Leuven, Belgium, this team would develop wearable technology that can be used in daily life to capture more data than ever before. This information ranging from symptoms and physical activity to heart function and air quality could be used alongside genetic and healthcare data to transform diagnosis, monitoring and treatment of heart and circulatory diseases through the creation of a digital twin.

Cure heart

This project aims to provide a cure for inherited, killer heart muscle diseases. Led by Professor Hugh Watkins, BHF chair of cardiovascular medicine at the University of Oxford, these researchers will develop a treatment that targets and silences the faulty genes responsible for cardiomyopathies diseases of the heart muscle that can lead to sudden death at an early age. They intend to combine a deep understanding of underlying genetic mechanisms with new technologies, to stop the progression of the damage caused by genetic heart muscle diseases, or even reverse the damage.

Professor Sir Nilesh Samani, medical director at the British Heart Foundation, said: Heart and circulatory diseases remain the number one cause of death worldwide.

Were taking small steps forward every year but whats needed is a giant leap, which wont be achieved by a business-as-usual approach.

The Big Beat Challenge embodies our ambition to turbo-charge progress and could lead to its own man on the moon moment. I have absolutely no doubt the winning idea will define the decade in their area.

The teams will prepare their final applications by June 14, with interviews in early September and a decision expected by the end of the year.

Read more

Our guide to the Cambridge Science Festival 2020

Can HIV be cured? Evelyn Trust-funded research at University of Cambridge probes viral latency

Inside the Cambridge lab in pole position to create a new coronavirus vaccine

Sanger Institute scientist helps unveil blueprint for extraordinary Human Cell Atlas

Prof Greg Hannon on taking over at the Cancer Research UK Cambridge Institute and creating the worlds first virtual reality tumour

Read more from the original source:
Prof Ziad Mallat leads Cambridge effort to win 30m to tackle leading cause of heart attacks and strokes - Cambridge Independent

Aspiration-assisted bioprinting for precise positioning of biologics – Science Advances

INTRODUCTION

Aggregated cells have been formed into spheroids (13), honeycombs (4), and strands (5) from a variety of different cell types and their cocultures. They have many advantages including the cellular capability to secrete extracellular matrix (ECM) components with an effective communication between cells in a native-like microenvironment (1). When cells are grown in an isolated fashion (i.e., cells in monolayers or cell-laden hydrogels), they usually do not facilitate native-like tissue microenvironment because of limited cell-cell and cell-ECM interactions (6). Three-dimensional (3D) cell aggregates, particularly tissue spheroids, are excellent candidates to mimic in vivo tissue microenvironments, which can be reconstituted to form reproducible complex tissues [such as bone (7) and pancreas (8)] and or tissue models [cancer (9)]. Furthermore, cocultured aggregates can be used as building blocks for fabricating scalable tissue complexes (2). Spheroids loaded with endothelial cells can also facilitate a denser tissue microenvironment, inherent ECM secretion, and prevascularized network (10). As a result, large-scale vascularized tissue complexes can be biofabricated using prevascularized cell aggregates as fundamental building blocks (7, 11), which allow more accurate representations of native tissues. Moreover, these tissue complexes stand to develop physiologically correct models for drug screening, disease modeling (i.e., cancer), and high-throughput screening (12). Therefore, various advantages of tissue spheroids make them a great candidate as building blocks for 3D bioprinting.

Despite these advantages, only a few methods including extrusion-based bioprinting (2, 11, 13, 14), droplet-based bioprinting (15), Kenzan (16), and biogripper approaches (4, 17) have been demonstrated for 3D bioprinting of spheroids made of cells, such as but not limited to human articular or nasal chondrocytes, human umbilical vein endothelial cells (HUVECs), human umbilical vein smooth muscle cells, etc. Extrusion-based bioprinting technique dispenses similar-sized spheroids suspended in a hydrogel ink through a glass nozzle. During bioprinting, spheroids in the hydrogel ink may self-aggregate inside the nozzle, leading to clogging issues (2). Although extrusion-based bioprinting of cellular aggregates in the form of strands can generate scalable tissues (3, 5), their use in high-precision applications, such as organ-on-a-chip platforms or microphysiological systems, is quite challenging. In droplet-based bioprinting, a single spheroid is loaded into a droplet during bioprinting, which enables the positioning of spheroids in 2D (15). Kenzan method uses an array of needles on which spheroids are skewered by a robotic arm; however, this method requires same-size spheroids since bioprinted spheroids have to fit properly in the needle array and smaller spheroids would be prone to fragment during insertion on the needle (16). Recently, the biogripper technique was introduced to manipulate defined micromolded tissue blocks. However, this technique enables bioprinting of only molded tissue blocks in the range of 600 m to 3.4 mm, where submillimeter scale is quite large for typical tissue building blocks (4, 17). All the existing techniques used in the literature suffer from the positional accuracy and precision of spheroid bioprinting; may induce substantial damage to biological, structural, and mechanical properties of spheroids; and are limited to the use of same-size spheroids for successful bioprinting.

Here, we present a new hybrid bioprinting approach through harnessing the power of aspiration forces, which enables us to pick and precisely bioprint a wide of range of biologics, with dimensions in an order-of-magnitude range (80 to 800 m), into/onto a gel substrate with minimal cellular damage. To better understand the response of biologics to the bioprinting process, we unveil the underlying mechanism explaining the physical behavior of viscoelastic spheroids and their interactions with physical governing forces during aspiration, lifting, and bioprinting. Compared to the abovementioned methods, the presented approach facilitated the bioprinting of spheroids in higher positional precision and accuracy, ~11 and ~15% with respect to the spheroid size, respectively. In addition, it enabled bioprinting in 3D with flexibility of bioprinting of nonuniform, any-size spheroids into (i) a functional gel as a scaffold-based approach or (ii) a sacrificial gel as a scaffold-free approach (Fig. 1). The newly developed aspiration-assisted bioprinting (AAB) platform, modified from a MakerBot Replicator 1 (<$1000) (see fig. S1), operates a custom-made glass pipette, which is used to pick up biologics and 3D bioprint them into or onto a gel substrate. AAB was coupled with microvalves for droplet-based bioprinting of functional or sacrificial hydrogels. To bioprint spheroids into a functional hydrogel (i.e., fibrin), fibrinogen and thrombin layers were printed via microvalve bioprinting to obtain fibrin constructs. Spheroids were then bioprinted into desired positions before the constructs were fully cross-linked. To bioprint spheroids onto a sacrificial hydrogel (i.e., alginate), microvalve bioprinting and aerosol cross-linking processes were used. The first step included the generation of sodium alginate droplets on a glass substrate. Second, calcium chloride (CaCl2) was fumed for instant cross-linking (18). Spheroids were then picked and 3D bioprinted onto the partially cross-linked alginate. Next, the print area was overlaid with sodium alginate droplets. Then, aerosol form of CaCl2 was applied again. The process was then repeated as many times as needed for building other layers. Next, bioprinted spheroids were maintained in the support gel temporally until partial fusion was realized. Last, the support gel was gently removed through decross-linking using a lyase solution.

In step 1, spheroids are picked from the cell media by a glass pipette, where required back pressure is set to lift spheroids. Afterward, spheroids can be bioprinted into sacrificial hydrogels (scaffold-free bioprinting) or functional hydrogels (scaffold-based bioprinting). In this regard, in step 2, microvalve bioprinting is used to bioprint a gel substrate, which can then be partially cross-linked using various different cross-linking schemessuch as but not limited to enzymatic, photo, and ionic cross-linkingas highlighted in step 3. Next, in step 4, spheroids are bioprinted precisely into designed positions, and spheroid bioprinting is repeated as many times as needed. Steps 2 to 4 can be repeated as needed. In step 5, bioprinted tissues are isolated from the support hydrogel (for scaffold-free bioprinting) or further grown in the functional hydrogel (for scaffold-based bioprinting). UV, ultraviolet.

The presented approach paves the way for bioprinting several tissue types and a wide range of spheroids in 2D and 3D in gel substrates with multiple applications presented throughout this paper, including (i) the development of physiologically relevant culture environments to demonstrate the collective angiogenic sprouting behavior of spheroids in a scaffold medium and (ii) fabrication of osteogenic tissues to decode the role of midterm osteogenic induction of stem cellbased spheroids (before bioprinting) on the mineralization and assembly behavior in a scaffold-free environment. In addition to spheroids, other living cells and tissue building blocks, including electrocytes from electric eel and tissue strands, can be bioprinted for a wide variety of applications, such as but not limited to tissue engineering, regenerative medicine, drug testing and pharmaceutics, disease modeling, microphysiological systems, biophysics, and biocomputing.

In the AAB process, the first step is to pick a spheroid (fig. S2) and then lift it and drag it rapidly outside the culture media by aspiration forces as shown in Fig. 2A. The spheroid should be captured with a minimum aspiration force to transfer but not break or damage it. During aspiration under an applied stress (), a spheroid with viscoelastic properties exhibits both viscous and elastic properties (19). It exhibits elastic properties like a solid at times shorter than relaxation time and like a fluid for t > , which can be described by the Maxwell modelddt+=ddt(1)where is the strain and is the modulus of elasticity of spheroids. During this process, two major impediments were experienced. First, spheroids were prone to fragment because of low cellular cohesivity and elasticity even under very low pressure levels. Second, detachment of spheroids from the pipette tip at the three-phase contact (air-liquid-tissue) was observed during lifting. The former can be mitigated by engineering of spheroids to attain better elastic properties [such as culturing them longer (20) or incorporating cells expressing higher cell-cell and cell-matrix adhesion or ECM proteins (21)], and the latter can be addressed by determining the minimum aspiration pressure (critical lifting pressure). A spheroid is lifted by pipette aspiration after overcoming gravity, buoyance force, hydraulic drag, and thermodynamic barrier at the interface. The main difficulty in lifting a spheroid is the binding energy caused by the surface tension at the interface between the culture media and air. The spheroid contributes to the lifting barrier in the form of a contact angle at the three-phase (tissue, air, and media) contact line. The energy barrier to lift a spheroid into air can be expressed asE=As1,2cos2d2(2)where As is the surface area of a spheroid, 1,2 is the surface tension between the media and air, and d is the contact angle at the three-phase contact line. During lifting, the three-phase contact angle (dynamic contact angle) is greater than the static contact angle because of dynamics effect (22). The dynamic contact angles of spheroids made of several types of cells were enumerated in table S1. By comparison, the thermodynamics barrier is about 500 times of gravity, 100 times of Stokes drag, and 5 times of Young-Dupre critical pressure. During lifting, the energy barrier can be estimated by adding a geometrical correction factor (m) as a result of slight changes in the spheroid geometry due to the aspiration of a tongue (see Fig. 2B). The initial contact length of the tongue (ht=0) of a spheroid ranges between Rp and 2Rp. Thus, m can be defined as followsm=14Rp24RS24Rp2=1Rp2RS2Rp21(RpRs)2(3)

In Eq. 3, Rp is the pipette tip radius and Rs is the spheroid radius. m can be approximated to 1 when the spheroid radius is much larger than the radius of the pipette tip. However, when lifting a small spheroid or when the radius of the pipette is comparable to that of the spheroid, m becomes much smaller. Consequently, the critical lifting pressure of a spheroid (PC) from the media can be expressed as follows (22)PC=mFmax/Ah=2mRS1,2cos2d2/(Rp2)(4)

The critical lifting pressure is proportional to the surface tension coefficient of the media-air interface, the radius of the spheroid, the dynamic contact angle at the three-phase contact line, and the tapered angle of the pipette (influences Rp, but this parameter was fixed).

(A) Time-lapse images during spheroid lifting process (at the interface of cell media and air). (B) A schematic showing physical parameters involved in lifting of a spheroid from the cell media. (C) SEM images, (D) surface tension (n = 5), and (E) the normalized collagen content of HUVEC, 3T3, 4T1, HDF, MSC/HUVEC, and MSC spheroids (compared to HUVEC spheroids) at day 2 (n = 4; *P < 0.05, **P < 0.01, and ***P < 0.001). (F) Critical lifting pressure to lift spheroids (in the range of 200 to 600 m in diameter) (n = 5). The experimental data spread under the theoretical curve, which was determined using the experimental data for 4T1 spheroids with parameters (d = 64 and s1,2 = 57.4 mN/m). Spheroids made of other cell types had lower theoretical critical lifting pressure values (data are not shown in the paper). For instance, the theoretical critical lifting pressure for HUVEC spheroids was 20% smaller than that of 4T1 spheroids. (G) Viscoelastic behavior of spheroids under aspiration (n = 3). Here, h denotes the advancement of spheroids inside a glass pipette. The aspiration experiment used a similar pipette as that in bioprinting. The aspiration pressure was determined according to the size of spheroids satisfying the condition that spheroids could be lifted from the cell media.

To demonstrate picking and lifting of spheroids, we fabricated a wide range of spheroid types with different viscoelastic and surface tension properties using HUVECs, mouse fibroblast cell line (3T3), mouse mammary carcinoma line (4T1), human dermal fibroblasts (HDFs), coculture of human mesenchymal stem cells (MSCs) and HUVECs, and MSCs. Various kinds of spheroids in a diameter range of 200 to 600 m were obtained using cell-repellent 96-well plates. Spheroids were fabricated at a cell density from 2500 to 10,000 per spheroid and cultured for 1 to 3 days (fig. S3A). During the first 24 hours, we closely monitored spheroid formation and observed that 3T3 and HDF spheroids became compact and withstood aspiration forces at the end of 20 hours, while others became compact at 24 hours, implying that these spheroids could be lifted anytime thereafter (fig. S4). To investigate the ultrastructure of spheroids, spheroids were analyzed by scanning electron microscopy (SEM), and SEM images demonstrated clear differences in surface morphology and compactness of different spheroids cultured for 2 days (Fig. 2C). The surface topology of MSC spheroids displayed a substantial amount of secreted ECM with smoother and more compact structure due to tight cell-cell and cell-ECM interactions. On the other hand, the surface topology of HUVEC spheroids displayed lesser ECM compound, which resulted in a pitted surface and tiny gaps between cells. To lift spheroids, spheroids were required to be compact and captured in the cell media and to withstand aspiration forces. Spheroids also have surface tension, with each cell being analogous to a liquid molecule (23, 24). Thus, surface tension of spheroids were investigated by a micropipette aspiration technique (19, 25) according to the Young-Laplace equation, which gave the relationship between the internal pressure of spheroids and cell media across a curved interface. According to the Young-Laplace equation, the surface tension coefficient can be estimated as =P2(1/Rp1/Rs), where P is the equilibrium aspiration pressure when the advancement of the spheroid inside the pipette was the same as the radius of the pipette tip. As shown in Fig. 2D, the surface tension of HUVEC, 3T3, 4T1, HDF, MSC/HUVEC, and MSC spheroids at 2 days of culture were measured to be ~14, 30, 37, 41, 51, and 66 mN/m, respectively. Surface tension of MSC-only spheroids was approximately five times higher than that of HUVEC spheroids. It is worth mentioning that Norotte et al. (26) used a different method to measure the surface tension of spheroids and obtained a similar result for HUVEC spheroids. While the surface tension of 4T1, HDF, and MSC/HUVEC spheroids increased over time, the surface tension of spheroids made from other cell types maintained similar properties during the 3-day culture (fig. S3B). This time frame, on the other hand, can vary for spheroids prepared using other techniques, such as but not limited to handing drop, microfluidic, rotator flask, and liquid overlay methods (27). Our results indicate that there is a positive correlation between the surface tension of spheroids and their compactness, confirming previous findings by Foty and Steinberg (28). In addition, the total collagen amount of spheroids was investigated using a hydroxyproline colorimetric assay kit since collagen is one of the major ECM components of spheroids (3). The measured collagen amount for 3T3, 4T1, HDF, MSC/HUVEC, and MSC spheroids at day 2 was ~1.4-, 1.4-, 1.5-, 2.8-, and 3.4-fold higher compared to that for HUVEC spheroids, respectively (Fig. 2E). The normalized collagen content in different spheroids showed a similar trend as compared to the compactness of spheroids; however, we did not observe any notable differences among the normalized collagen content for 3T3, 4T1, and HDF spheroids. A recent study reported a positive correlation between compactness of cell aggregates and their collagen expression (29).

Figure 2F denotes a linear relationship between the critical lifting pressure and diameter of spheroids (in the range of 200 to 600 m). When the diameter of spheroids increased, the critical lifting pressure also increased. The theoretical critical lifting pressure for each spheroid types at different diameters were determined using Eq. 4, where the maximum theoretical value belonged to 4T1 spheroids, which could be used as a baseline for other spheroid types to be tested during aspiration. In addition, the minimum critical lifting pressure among all spheroids types (from 200 to 600 m) was determined to be ~19 mmHg. The difference between the theoretical and experimental value of the critical lifting pressure was due to (i) the irregular shape of spheroids (elliptic or pancake-like) influencing the maximum energy barrier (30, 31) and (ii) the measurement inaccuracy of the pressure sensor (which was around 10%; see fig. S5, A and B). Another vital factor for successful bioprinting was to determine viscoelastic properties of spheroids, which were reflected by the relationship between stress and strain as a function of time. During the AAB process, spheroids were kept within a solid elastic regime. The operation time of AAB was defined by the elapsed time between spheroid picking and bioprinting, which was commonly less than 30 s. Therefore, spheroids were successfully bioprinted, while their relaxation time () was longer than the bioprinting operation time. For this reason, we plotted the aspiration curves of various spheroids (Fig. 2G). At the early stage of aspiration, spheroids deformed very quickly within the elastic regime. Then, after a relaxation time, accumulated stress was gradually released, and spheroids experienced a relaxation process and return to their original shapes. As shown in Fig. 2G, the relaxation time for HUVEC, 4T1, and MSC/HUVEC spheroids were around 3 to 5 min. The relaxation time for HDF spheroids could reach up to 18 min. Overall, these relaxation times were sufficient to assure successful bioprinting without permanent deformation to spheroids.

After lifting spheroids from the cell media and transferring them to the bioprinting stage, the back pressure was released, and the spheroids were fully recovered or, in other words, they returned to their original shapes as bioprinting time was less than the relaxation time. To bioprint a spheroid, the spheroid was partially submerged into a precross-linked or partially cross-linked gel substrate, as going deeper could result in their breakage due to penetration of the pipette tip into the spheroid. When the nozzle moved up, the spheroid was stuck to the gel because of adherence between the spheroid and the gel (Fig. 3A1), released from the pipette, and deposited into the gel. In AAB, successful bioprinting was determined by a constant adherence at the pipette tip (upward, Fup) and a variable bioprinting force at the interface of gel (downward, Fdown). To determine Fup, two angles were defined: 1=arccosRpRs, and 2 is the pipette taper angle. Fup can be expressed as Fup = 2Rps cos (1 + 2), where s is the surface tension of the spheroid. At the bottom of the spheroid, the maximum force pulling the spheroid downward due to the surface tension of the gel substrate, i.e., the maximum bioprinting force provided by the gel, can be expressed as Fdown=2Rsgcos2(12). Here, g is the surface tension of the gel, and 1 is the effective angle of wetting. For successful bioprinting, the maximum force pulling the spheroid downward needs to overcome the surface tension adherence at the tip of the pipette. Thus, successful printing, as shown in Fig. 3A2, needs to satisfy the condition Fdown > Fup. However, if a spheroid is not fully recovered (when the spheroid is submerged rapidly into the gel), there can be an extra stress (Fext) at the pipette tip. The extra stress may increase the difficulty of bioprinting since Fdown needs to overcome Fext + Fup.

(A1) A schematic showing critical parameters during bioprinting. (A2) An image from the traveling camera showing spheroid placement onto a gel substrate. Fluorescent images showing (A3) PSU and (A4) matrix patterns. GFP+ MSC spheroids were patterned onto (A5) COL I and (A6) gelatin-methacryloyl (GelMA). (A7 and A8) Images showing that eight fixed spheroids were bioprinted on top of each other in air without any gel support during bioprinting. DAPI, 4,6-diamidino-2-phenylindole. (B1) Time-lapse images of self-assembly process after bioprinting of 1-day cultured 3T3 spheroids at 0, 24, 48, and 72 hours (B2) and the normalized contact length and intersphere angle of fusing spheroids up to 24 hours. (B3) Cell viability of 3T3 spheroids that were not treated with bioprinting (control), after bioprinting inside the cell media (case 1), and after bioprinting into a gel substrate (case 2) (n = 3; *P < 0.05). CMTMR, 5-(and-6)-(((4-chloromethyl)benzoyl)amino) tetramethylrhodamine; CMFDA, 5-chloromethylfluorescein diacetate. (C1) Hematoxylin and eosin staining from the sagittal plane of a tail segment of electric fish showing stacked electrocytes in series. (C2) The SEM image of a single electrocyte. (C3) Calcein staining of bioprinted electrocytes. (D) A bioprinted cartilage tissue strand between pins. Photo credit: Bugra Ayan, Penn State University.

To verify the presented theoretical approach, we measured 1, 2, and 1 angles and obtained the surface tension of precross-linked gel [1% (w/v) alginate] from the literature (32). The results indicated that Fdown was ~32, 14, 12, 11, 9, and 7 times greater than Fup for HUVEC, 3T3, 4T1, HDF, MSC/HUVEC, and MSC spheroids, respectively, as enumerated in table S2. Surface tension of gel solutions can vary from gel to gel. In some gels [such as alginate (32)], surface tension is dependent on concentration; however, there are hydrogels where surface tension is not dependent on concentration, such as polyacrylamide (33). Therefore, we cannot make a general statement on the correlation between concentration and surface tension. In addition, concentration of the gel should also be compatible with microvalve bioprinting, as higher concentrations of precursor solutions are, in general, bioprintable as such concentrations can support droplet formation (34). For bioprinting into a gel substrate, the gel precursor solution should be flowable as well so that the solution can overlay the bioprinted spheroid quickly; therefore, we performed bioprinting on partially cross-linked or uncross-linked gel precursor.

Before performing the patterning and 3D bioprinting of spheroids, we first inspected the quality of positioning during bioprinting. In this regard, agarose beads (with near-perfect sphericity) and the motion stage of the 3D bioprinter were used as control groups. The positional precision and accuracy for the motion stage (empty pipettes), spherical agarose beads (ranging from 250 to 300 m in diameter), and 2-day cultured MSC/HUVEC spheroids (~300 m in diameter) were determined to be ~2 and 2.1 m, 14.4 and 10.4 m, and 34.7 and 45.9 m, respectively (fig. S5, C to E). The results indicate that the bioprinter motion stage had a small effect on the positional error during bioprinting and that bioprinting of spheroids was about two- and fourfold less precise and accurate compared to printing of agarose beads, respectively. This could be due to the viscoelastic nature, lesser sphericity, and slightly higher average diameter of tissue spheroids compared to more rigid agarose beads. We demonstrated the ability to bioprint spheroids precisely (~11% with respect to the average spheroid size) onto alginate through patterning of various shapes (fig. S6, A1 to A3), initials of Penn State University (PSU) (Fig. 3A3), and a matrix of spheroids of various shapes and dimensions (including irregular shapes) in the diameter range of 80 to 200 m (made of HUVEC, 3T3, and 4T1 cells) (Fig. 3A4). Moreover, we also demonstrated the bioprinting of green fluorescent protein (GFP)labeled MSC spheroids in the shape of triangle and ring into other gels, including type I collagen (COL I) and gelatin methacryloyl (GelMA), as shown in Fig. 3 (A5 and A6, respectively). To highlight the unprecedented precision of AAB, we bioprinted eight different-sized MSC spheroids on top of each other without any gel support (Fig. 3, A7 and A8) and also fabricated a hollow bridge shape with MSC spheroids using the same approach (fig. S6, B1 and B2). Moreover, we demonstrated another example of a hollow bridge configuration, where the middle spheroid in the second layer was supported by the underlying gel without any spheroid support underneath (fig. S7). This was accomplished by bioprinting the gel and spheroids alternatingly at each layer, which necessitated the precise control of gel thickness; however, the gel thickness was dependent on several factors, such as the droplet resolution, cross-linking time, and spreading behavior of droplets, which were not trivial to control at the same time using microvalve bioprinting. To overcome this fundamental limit, self-healing Bingham plastic support gels (35) could be used to freely move the spheroids inside gels, which may bring more flexibility in self-assembly of highly complex geometries including hollowed-out structures.

In addition, self-assembly of spheroids was investigated at predetermined time points. As shown in Fig. 3B1, 3T3 spheroids were bioprinted into fibrin with close proximity and then cultured for 72 hours. The two individual 3T3 spheroids bioprinted next to each other gradually fused to form a larger spheroid to minimize their surface energy, as described in a previous study (21). The normalized contact length and intersphere angle increased by 50% over the first 24 hours of culture (Fig. 3B2). To evaluate the role of bioprinting on the viability of spheroids, two cases were evaluated. In case 1, the viability of spheroids was determined immediately after lifting spheroids and depositing them into another cell medium reservoir. In case 2, the viability of spheroids was evaluated after bioprinting them into the gel substrate. Spheroids, which were not subjected to the bioprinting process, were used as a positive control group. The viability of spheroids in the positive control group and case 1 were determined to be ~94 and ~88%, respectively (Fig. 3B3). In case 2, cell viability was measured to be ~82%. The decrease in cell viability could be due to the aspiration force or dehydration during the rapid transfer or cell damage when spheroids were submerged into the hydrogel substrate; however, viability levels over 80% for bioprinting of spheroids could still be considered moderate, as viability of fabricated cells aggregates even without bioprinting could be in that range (36).

In addition to bioprinting of spheroids, the AAB system also enabled the bioprinting of other biologics. For example, we demonstrated the bioprinting of electrocytes isolated from electrogenic organs of electric fish. Because of the asymmetric functionality of their anatomy and their spatial arrangements in series configuration in an electric organ (similar to batteries connected in series; Fig. 3C1), electrocytes produce a considerable amount of electricity (37). In this study, five electrocytes (~400 m in diameter; Fig. 3C2) from weakly electric fish (Brachyhypopomus gauderio) were obtained according to the animal protocol (Institutional Animal Care and Use Committee #47870) and patterned next to each other onto agarose using AAB with a back pressure of ~20 to 25 mmHg (Fig. 3C3). To the best of our knowledge, this is the first bioprinting of electrocytes, which can be used in biofabrication of biological batteries for various applicationssuch as pacemakers, cochlear implants, and brain chipsin the future (38). In addition, these cells could be arranged in the form of biological circuits for biocomputing or as bioelectric interfaces for use in treating limb loss, musculoskeletal disorders, and body augmentation as well as cyborg organs interfacing electrical devices and biology (39). The presented approach showed the possibilities of bioprinting not only spheroids or single cells but also irregularly shaped aggregates. For example, Fig. 3D shows vertical bioprinting of tissue strands [described in our previous work (5)] into the space between pins, which can be used for fabrication of scalable tissues of muscle, fat, cartilage, nerves, blood vessels, etc.

To demonstrate other unique capabilities of the presented approach, heterogeneous tissue complexes were 3D bioprinted using spheroids of different sizes and types including tdTomato+ HUVEC spheroids (~155 m) and GFP+ MSC spheroids (~390 m) (Fig. 4, A and B). Spheroids were arranged into a pyramid structure to clearly visualize the heterogeneous architecture using confocal imaging, where alginate was used as a sacrificial gel and the first, second, and third layers constituted of HUVEC, MSC, and HUVEC spheroids, respectively. This example clearly demonstrates the unique deposition ability of the AAB technique, as the last HUVEC spheroid was accurately placed into the small and confined space between three adjacent MSC spheroids (~2.5-fold of HUVEC spheroid size) on the third layer. Alginate preserved the structural integrity of the bioprinted pattern during the initial stage of culture. Moreover, it enabled the bioprinted entities to stick in their precise locations, which were defined before the bioprinting process. To print the sacrificial alginate, we used a unipolar wave pulse with a dwell voltage (amplitude) of 5 V and a dwell time (valve opening duration) of 1000 s for actuating the microvalve dispenser, where a positive back pressure of ~103 kPa was used for driving the flow of sodium alginate inside the tubing. The reader is referred to fig. S8A for the optimization of dwell time and droplet volume. Afterward, sodium alginate layer was partially cross-linked with aerosol form of CaCl2 for 30 s, and spheroids were bioprinted as explained in Fig. 1. Patterned spheroids were partially fused and maintained their initial position after 48 hours of incubation. After 2 days of culture, alginate was gently dissolved [using an alginate lyase as explained in our earlier work (5)], and the bioprinted constructs maintained their integrity even after the sacrificial alginate was removed. As evident from the confocal images (Fig. 4, C1 to C6), spheroids were well connected in 3D. A similar arrangement was also presented with MSC spheroids of three different dimensions, where spheroids got larger as more layers were laid down (fig. S9, A to C). We also demonstrated a more complex pattern such as a 3D diamond pattern with MSC/HUVEC spheroids (Fig. 4, D to G). To the best of our knowledge, this is the first bioprinting of tissue spheroids with such a positional accuracy, ~15% with respect to the spheroid size, yielding highly intricate geometries and heterogeneous structures in 3D.

(A) A schematic illustration of 3D bioprinting of a heterogeneous pyramid construct using different sizes and types of spheroids. (B) A photograph of the bioprinted three-layer heterogeneous pyramid. (C1 to C6) 3D reconstruction of confocal images of bioprinted pyramid of tdTomato+ HUVEC spheroids (first and third layers) and GFP+ MSC spheroids (second layer). (D) A schematic illustration of a diamond construct made of MSC/HUVEC spheroids. (E) A photograph showing 3D bioprinted diamond from the side camera. (F) Fluorescent images of the bioprinted diamond, which were stained with DAPI, CD31, and F-actin. (G1 to G4) Confocal images of the diamond construct (bottom view) (note that 1-day cultured HUVEC and 2-day cultured MSCs were used in these experiments). Photo credit: Bugra Ayan, Penn State University.

In this study, we have demonstrated the utilization of AAB in both scaffold-based and scaffold-free configurations and presented two unique applications demonstrating its potential in the development of physiologically relevant culture environments for studying angiogenic sprouting and fabrication of osteogenic tissues for tissue engineering purposes. To demonstrate the application of AAB in scaffold-based fabrication of physiologically relevant culture environments, we bioprinted HUVEC spheroids into fibrin hydrogel with a predetermined distance apart and studied their collective angiogenic sprouting behavior. This importantly signifies that angiogenic sprouting behavior can be tailored by varying the proximity of spheroids, hence directly affecting cell-cell signaling. To study the effect of distance on angiogenic sprouting, we deposited droplets of fibrinogen (6 mg/ml) [loaded with HDFs (0.5 million/ml)] and thrombin (2.4 U/ml) layer by layer (in 1:1 volume) to fabricate fibrin constructs, as such concentration ranges support angiogenesis of HUVECs (40). A positive back pressure of ~103 kPa was used for driving the flow of fibrinogen and thrombin solutions inside the tubing and dispenser. To dispense a ratio of 1:1 of fibrinogen and thrombin, we used dwell times of 500 and 700 s for obtaining the same droplet volumes at the microvalve dispensers, respectively. The reader is referred to fig. S8 (B and C) for the optimization of droplet generation for fibrinogen and thrombin solutions. HUVEC spheroids were then bioprinted into fibrin before complete gelation. The distances between the spheroids were maintained at 400 10, 800 13, and 3000 16 m (isolated spheroids used as a control group) (Fig. 5A1). Bioprinted constructs were cultured for a period of 7 days. Angiogenic sprouting from HUVEC spheroids at days 2, 5, and 7 was quantified using AngioTool software (41). Spheroids with close proximity to each other were seen to have higher total vessel length as compared to isolated spheroids right from the initial stages of culture. The combined length of sprouts was 13 and 11 mm for 400 and 800 m, respectively, as compared to the control group, which were around 6 mm (Fig. 5A2). A similar trend was also observed for the total vessel area. There was approximately 3- and 2.5-fold increase in the vessel area for 400- and 800-m distances on day 7 as compared to the control group, respectively. Although the total number of branching points or junctions was not significantly different among different groups at day 2, the sprouts branched more when spheroids were bioprinted close to each other, as compared to the control group (fig. S10). On day 7, the number of junctions for 400- and 800-m distances was 2.1- and 1.7-fold greater than those for the control group, respectively. The mean lacunarity refers to the amount of free space around the sprouted capillaries, and an increase in angiogenic sprouting results in a decrease in lacunarity (42). This yields a measurement of the sprouting activity, and the mean lacunarity was the highest for the control group compared to other two groups.

(A1) Epifluorescent images of bioprinted tdTomato+ HUVEC spheroids with varying distances (400 to 3000 m) apart on day 7. (A2) Graphical representation of various sprouting propertiesnamely, total vessels length, total number of junctions formed, vessel area, and mean lacunarityobtained at day 7 for bioprinted HUVEC spheroids (n = 3; ***P < 0.001). (B1) Epifluorescent images of bioprinted GFP+ and tdTomato+ HUVEC spheroids with varying distances (400 to 3000 m) apart on day 7 along with higher-magnification confocal images of the interface region in XY and YZ planes showing capillaries formed by both GFP+ and tdTomato+ HUVECs (indicated by white arrows). (B2) Directionality analysis demonstrating the direction and percentage of normalized number of sprouts on day 7 (n = 3; *P < 0.05, **P < 0.01, and ***P < 0.001) [note that green and red bars demonstrate the angles of interest (AOIs), which are [60, 60] for GFP+ HUVECs and [120, 240] for tdTomato+ HUVECs]. (B3) Confocal images at the interface of two spheroids showing capillaries formed by both GFP+ and tdTomato+ HUVECs. (C1) A schematic illustration of the directionality of sprouts from a HUVEC spheroid toward a spheroid of GFP+ HDF and MSC cocultures. (C2) The directionality analysis for different mixing ratios of HDF:MSC, including HDF (control), 2:1, 1:1, and MSC (control), on day 7 (n = 3; ***P < 0.001 shows significance between AOI and Other for each group, and #P < 0.05, ##P < 0.01, and ###P < 0.001 show significance among AOIs of different groups) [note that N/A represents the none applicability of the directionality analysis, as no sprouts were observed in the MSC-only group; no directionality analysis was performed for the 3000-m distance, as sprouting was not observed and HUVECs exhibited spreading only; 1-day cultured HUVECs were used in all experiments; and the critical lifting pressure for coculture HDF/MSC spheroids (2:1 and 1:1 ratio) was determined to be 28.7 and 29.1 mmHg, respectively, through interpolation of the critical lifting pressure values for HDF and MSC spheroids presented in Fig. 2F].

In our study, HUVEC spheroids bioprinted with 400- and 800-m distances apart were considered to be in close proximity. On the other hand, HUVEC spheroids bioprinted with 3000-m distance apart were far enough to be considered isolated spheroids (control group). Proximity between cells triggers a cascade of events that, in turn, influences cellular behavior, and to study these events, it is important to control localization under in vitro conditions (43). The presented approach offers the capability of controlling the distance between spheroids and thus aims to better understand this signaling between spheroids. Sprouting properties such as vessel length, junction formation, and vessel area were all enhanced when spheroids were close to each other as compared to when they were placed far apart. The presence of HDFs in the matrix surrounding HUVEC spheroids also reinforced the formation of stable sprouts. It is known that fibroblasts act as supporting cells and surround the capillary-like structures, which gradually develop by self-organization of endothelial cells and simultaneous degradation of fibrin matrix (44). Moreover, fibroblasts secrete various soluble growth factors such as vascular endothelial growth factor (VEGF), angiopoietin-1, platelet-derived growth factor (PDGF) (45, 46), which enhance and modulate the growth of angiogenic sprouts (47). Bioprinted HUVEC spheroids close to each other probably up-regulated the combined secretion of these growth factors in the vicinity of the spheroids, which led to enhanced sprouting properties. The sprouts from closely placed spheroids extended toward each other and gradually fused to form a capillary network.

To better understand whether the positioning of spheroids affected their collective angiogenic sprouting behavior, GFP+ and tdTomato+ HUVEC spheroids were bioprinted into fibrin gel (with same properties as discussed before) at 400-, 800-, and 3000-m distances apart, and cultured over a period of 7 days (Fig. 5B1). A directionality analysis was then performed to investigate the role of the presence of a nearby spheroid on the directionality of angiogenic sprouting. Thus, the angle made by each sprout with the horizontal line (0/180) was measured for all spheroids. The angle spans [60, 60] for GFP+ HUVEC and [120, 240] for tdTomato+ HUVEC spheroids, where sprouts primarily grew toward the other spheroid, were considered the angles of interest (AOIs), as highlighted in Fig. 5B2. On day 7, the percentage of normalized number of sprouts (where the total number of sprouts were normalized with respect to the total angle span) in AOI was significantly higher than that of the other angle span (indicated with Other) for 400- and 800-m distances, indicating a dominating directionality of angiogenic sprouting toward the other spheroid. The percentage of normalized number of sprouts for AOI was ~63 and 65 for GFP+ and ~59 and 61 for tdTomato+ HUVEC spheroids, for 400- and 800-m distances, respectively. Although the directionality of sprouts for all cases may not be very apparent on day 2 (initial stages of culture; fig. S11, A1 and A2), on day 5 (later stages of culture; figs. S11, B1 and B2, and S12), mature sprouts were more concentrated within AOI. In addition, for sprouts formed in directions falling outside the AOI (depicted in gray), we observed more random growth of sprouts over time. The sprouts for spheroids that were 3000 m apart were random and did not indicate any directionality from days 2 to 7 (Fig. 5B2, bottom, and fig. S12C). For 400-m distance, it was also observed that the GFP+ HUVECs suppressed the sprouting ability of tdTomato+ HUVECs day 2 onward, where higher numbers of GFP+ HUVEC sprouts were observed at the interface [see fluorescent images in fig. S11 (A1 to B1)]. Domination of GFP+ HUVEC sprouts could be due to the fact that GFP+ HUVECs in this experiment were from an earlier passage (passages 2 to 5) with respect to tdTomato+ HUVECs (passages 5 to 7) (48). In addition, we investigated whether sprouts from both spheroids interacted and thus performed confocal imaging at the interface close to the tdTomato+ HUVEC spheroid (Fig. 5B3). We noticed that some capillaries were formed by both GFP+ and tdTomato+ HUVECs, as shown by arrows, which could be due to vascular anastomosis or the migration of GFP+ HUVECs to the other side of the interface and their contribution to the capillary formation by tdTomato+ HUVECs spheroids. Overall, the results showed that HUVEC spheroids bioprinted close to each other influence each others sprouting behavior, which led to a well-organized network formation between the sprouting bodies.

In the abovementioned experiments, we investigated the role of multiple HUVEC spheroids on their collective sprouting behavior, where HDFs were bioprinted as a single-cell suspension in fibrin, had direct contact with HUVEC spheroids, acted as supporting cells, and aided in forming stable sprouts. To explore whether HDFs could still influence the sprouting behavior of HUVECs even when they were not in direct contact with HUVECs, we reconfigured the design of the experiments presented above. In this regard, a HUVEC spheroid was bioprinted along with a coculture spheroid of GFP+ HDFs and MSCs (with controlled distance apart), which enabled us to change the concentration of HDFs and study the differential effect of coculture composition on HUVEC sprouting. GFP+ HDF/MSC spheroids, in 2:1 and 1:1 ratios, were bioprinted next to tdTomato+ HUVEC spheroids in fibrin with the same properties as discussed before (Fig. 5C1). HDF and MSC (homocellular) spheroids were used as control groups. The distance between these spheroids were varied from 400 to 3000 m, as performed before. For the cases of 400 and 800 m, HUVECs were attracted toward spheroids of HDF, 2:1, and 1:1 groups and were seen arranging into sprouts over a period of 7 days (figs. S13 and S14). The directionality analysis on day 7 revealed that the percentage of normalized number of sprouts within AOI for HDF, 2:1, and 1:1 groups for 400-m distance were ~82, 80, and 67, respectively (Fig. 5C2). For 800-m distance, a similar directionality was observed, where the percentage of normalized number of sprouts within AOI for HDF, 2:1, and 1:1 groups were determined to be ~84, 81, and 76, respectively. On the other hand, spheroids in the MSC group (Fig. 5C2) or spheroids located apart with a 3000-m distance (fig. S15) did not induce sprouting day 2 onward; rather, HUVECs exhibited spreading behavior. On day 2, for the case of 800 m, although the tip cells from HUVEC spheroids were not observed to have any physical contact with HDFs at the interface of both spheroids, sprout-like structures were already formed (fig. S16A). These structures were directed toward HDFs, as the relevant directionality analysis revealed a significant difference between AOI and Other for HDF, 2:1, and 1:1 groups (fig. S16B). This could be due to the fact that HDFs communicated with HUVECs via paracrine signaling by the possible diffusion of secreted growth factors, such as VEGF, angiopoietin-1, and PDGF, as discussed before (45, 46). By day 5 when HDFs substantially migrated out of the coculture spheroids, HDFs interacted with HUVECs outside AOI, particularly within angle spans [60, 120] and [240, 300], and induced sprout formation in those directions (fig. S17). Overall, more stable sprouts were observed in HDF-involved spheroids, and the results revealed that better directionality of angiogenic sprouting could be attained when the density of HDFs increased in the coculture spheroid. The presence of MSCs, on the other hand, had a negative impact on angiogenic sprouting of HUVECs, which could be due to the inhibitory effect of MSCs on the angiogenic potential of HUVECs via cell-cell contact through modulation of the VE-cadherin/-catenin signaling pathway as described before (49, 50).

To demonstrate another major application of AAB, osteogenic tissues were bioprinted using MSC/HUVEC spheroids as building blocks in a scaffold-free configuration. After fabrication, two different osteogenic differentiation culture strategies were used, both with equal total exposure time of osteogenic induction. This was performed to decode the role of midterm osteogenic induction of stem cellbased spheroids (before bioprinting) on the mineralization and assembly behavior of generated tissues (fig. S18). In strategy no. 1, 2-day cultured spheroids were bioprinted into a triangle pattern (Fig. 6A). After bioprinting, triangle-shaped tissue complexes maintained their integrity and transformed into a more compact and dense structure after 3 days in proliferation culture conditions [growth media (GM)]. Spheroids in this triangle-shaped pattern self-assembled over time, where cells exhibited a viability of 83% after 5 days of incubation, and the assembled structure was further cultured for a period of 12 days in osteogenic media (OM) (Fig. 6, B and C). In general, MSCs cultured in OM express high levels of osteogenic markers (51). To confirm the osteogenic differentiation of bioprinted tissues, the early osteogenic differentiation marker, Runt-related transcription factor 2 (RUNX2), was used for immunohistochemical staining. At the same time, the presence of HUVECs was confirmed by CD31 staining. As shown in Fig. 6D, bioprinted tissues expressed osteogenic- and endotheliogenic-specific markers, as indicated by positive staining of RUNX2 and CD31. Calcium deposition of osteogenically differentiated tissues was also confirmed by Alizarin red staining. As shown in Fig. 6E, substantial calcium deposition was observed after 12 days of osteogenic induction, particularly at the core of the assembled tissue. As substantial contraction was observed after the fusion of MSC/HUVEC spheroids and the originally bioprinted triangular shape was not maintained (Fig. 6C) as well as the mineralization was not uniform throughout the tissue boundary (Fig. 6E), we also followed an alternative strategy (strategy no. 2) to preserve the bioprinted shape of osteogenic tissues (fig. S18). In this regard, MSC/HUVEC spheroids were first maintained in GM for 5 days, followed by inducting them with OM for 10 days. Next, spheroids were bioprinted and then kept for another 2 days in OM. In both strategies, the total exposure time to GM and OM was identical. At the end of culture (Fig. 6F), bioprinted tissues using strategy no. 2 exhibited strong expression of RUNX2 with more uniform distribution of mineralization demonstrated by Alizarin red staining, although RUNX2 staining was stronger in cores of spheroids (Fig. 6, G to J). Intensity analysis of RUNX2 revealed that RUNX2 staining was the strongest in the core of tissues or at the interface between spheroids and the weakest on the surface of the assembled tissues (Fig. 6, K and L, and fig. S19A), while CD31 staining was uniformly distributed throughout the histological sections of bioprinted tissues under both strategies (fig. S19B). A previous study demonstrated that HUVEC-mediated paracrine factors, including VEGF and the inflammatory mediator prostaglandin E2 (PGE2), promoted the osteogenesis of periodontal ligament stem cells under hypoxic conditions regulated by mitogen-activated protein kinase (MAPK) kinase/extracellular signalregulated kinase and p38 MAPK pathways (52). As the core of tissues and interface between spheroids were more hypoxic compared to the surface of assembled tissues, the osteogenic differentiation of MSCs could be further advanced in those regions by PGE2 and VEGF paracrine factors secreted by HUVECs. In addition, limited shape change was observed. This could be due to the fact that MSCs in MSC/HUVEC spheroids, cultured in OM for 10 days before bioprinting, were in the osteogenic differentiation pathway and their proliferation capability was diminished as reported in a previous study (53), and hence, limited contraction was observed in spheroids. Another advantage of strategy no. 2 is that the culture duration after bioprinting was reduced, where 2-day cultured tissues after bioprinting were still structurally stable. We also analyzed the expression levels of bone sialoprotein (BSP), type I collagen (COL1), alkaline phosphatase (ALP), RUNX2, and CDH2 (N-cadherin) genes for both strategies, and bioprinted tissues cultured in GM (labeled as 3D bioprinted tissue cultured with GM) and MSCs differentiated in 2D for 12 days (labeled as 2D MSCs cultured with OM) were used as control groups. As shown in Fig. 6M, expression levels of BSP, COL1, ALP, and RUNX2 genes for both strategies were similar to each other and significantly higher than those of control groups. In addition, the expression level of CDH2 gene (encoding N-cadherin protein) for all 3D bioprinted tissue groups were similar to each other and higher than that of the 2D control group. Overall, by changing the osteogenic induction window under the same total osteogenic induction duration, the shape of bioprinted tissues and uniformity of mineralization could be controlled, although no differences were detected in the expression levels of osteogenic genes.

Strategy no. 1: (A) Triangle-shaped tissue complexes were bioprinted using MSC/HUVEC spheroids and cultured for 3 days in GM and 12 days in OM. (B) Time-lapse images showing fusion of GFP+ spheroids up to day 15 (D15) after bioprinting. (C) An optical image showing the assembled tissue at day 15 after bioprinting. (D) Immunofluorescence staining (DAPI, CD31, F-actin, RUNX2, and DAPI + RUNX2) and (E) Alizarin red staining of the sectioned tissue. Strategy no. 2: (F) The final shape of the bioprinted tissue of osteogenic spheroids (cultured for 10 days in OM before bioprinting and 2 days in OM after bioprinting). Immunofluorescent images of (G) the bioprinted tissue and (H) confocal images of its histological sections stained for DAPI, CD31, and F-actin and (I) RUNX2 and DAPI + RUNX2. (J) Alizarin red staining of the tissue section. (K) Quantification of normalized RUNX2 intensity at different regions including the surface of assembled tissue, spheroid-spheroid interface, and core of spheroids (n = 50; **P < 0.01 and ***P < 0.001). (L) A representative heat map figure showing RUNX2/DAPI distribution in the surface of assembled tissue, spheroid-spheroid interface, and core of spheroids for strategy nos. 1 and 2. (M) BSP, COL1, ALP, RUNX2, and CDH2 gene expressions of 2D MSCs cultured in OM (control), 3D bioprinted tissues cultured in GM (control), and 3D bioprinted tissues cultured using strategy nos. 1 and 2 (n = 5; **P < 0.01 and ***P < 0.001).

Sodium alginate solution was made by dissolving 1% (w/v) sodium alginate (Sigma-Aldrich, UK) in deionized (DI) water. Calcium chloride solution was prepared by dissolving 4% (w/v) calcium chloride (CaCl2) (Sigma-Aldrich, St. Louis, MO) in DI water. For constructing fibrin scaffolds, fibrinogen (6 mg/ml) (Sigma-Aldrich) and thrombin (2.4 U/ml) (Sigma-Aldrich) were prepared for microvalve bioprinting. For bioprinting of electrocytes, agarose (A20070-100, Research Products International, IL) was dissolved in DI water to obtain a solution of 1% (w/v) agarose at 90C. COL I was extracted from rat tails according to a published protocol (54). GelMA was synthesized according to an established protocol (55). Detailed preparation methods of both materials can be found in the Supplementary Materials.

The mouse fibroblast cell line, 3T3, and the mouse mammary carcinoma line, 4T1, were obtained from the laboratory of A. Mastro, PSU (State College, PA). Culture media for 3T3 fibroblasts composed of Dulbeccos modified Eagles medium (DMEM) (Corning, Manassas, VA), supplemented with 10% fetal bovine serum (FBS) (Life Technologies, Grand Island, NY) and 1% penicillin-streptomycin (Corning). 3T3 cells were used at passages 22 through 27. 4T1 cells were grown in RPMI (Corning), 10% FBS, 1% penicillin-streptomycin. Passages 7 through 12 were used for 4T1 cells. HUVECs were purchased from Lonza and cultured in MCDB 131 base media (Corning) supplemented with 10% FBS (Corning), 1% glutamine (Gibco, Life Technologies), 0.5% bovine brain extract (Lonza, Walkersville, MD), heparin (10 U/ml) (Sigma-Aldrich), endothelial cell growth supplement (3 mg/ml) (Sigma-Aldrich), and 1% penicillin-streptomycin (Corning). HUVECs were used at passages 3 through 8. HUVECs were also transduced in house with EF1 tdTomato lentivector (Vectalys, Toulouse, France) to ease cell visualization for fluorescence microscopy according to the manufacturers instructions. GFP+ HUVECs were purchased from Angio-Proteomie (cAP-0001GFP; Boston, MA) and were used at passages 2 through 5. HDFs, obtained from N. Zavazavas laboratory at The University of Iowa (Iowa City, IA), were cultured in DMEM supplemented with 10% FBS (Corning), 1% glutamine (Gibco), 1% sodium pyruvate (Gibco), and 1% penicillin-streptomycin (Corning). HDFs were used at passages 7 through 12. GFP+ HDFs were purchased from Angio-Proteomie (cAP-0008-adGFP; Boston, MA) and were used at passages 2 through 6. MSCs were obtained from Lonza (Walkersville, MD) and RoosterBio (Frederick, MD) and cultured in SU-005 RoosterBasal-MSC (RoosterBio). Passages 4 through 8 were used for MSCs. GFP+ MSCs were purchased from Cyagen, cultured in SU-005 RoosterBasal-MSC (RoosterBio), and used at passages 2 through 6.

All cells were maintained at 37C in a 5% CO2 humidified atmosphere. Cell culture medium was changed every 2 to 3 days. Subconfluent cultures were detached from the flasks using a 0.25% trypsin0.1% EDTA solution (Life Technologies) and split to maintain cell growth.

Adherent cultures of each cell type were detached from the culture vessels with 0.25% trypsin-EDTA (Life Technologies, Grand Island, NY) solution. Trypsin was neutralized with appropriate GM, and cells were counted by a hemocytometer. Each cell type was then diluted to a concentration of 2500, 5000, and 10,000 cells in 200 l of appropriate GM. The cell suspension (200 l) was then pipetted into a single well of a U-bottom 96-well microplate with a cell-repellent surface (Greiner Bio-One, Monroe, NC). For fabrication of MSC/HUVEC spheroids made of 50,000 cells, MSCs and HUVECs were combined at a ratio of 92:8. The microplates were then incubated at 37C in a 5% CO2 humidified atmosphere. Spheroid formation was monitored daily on an EVOS FL cell imaging system (Life Technologies). For fabrication of GFP+ HDF/MSC coculture spheroids, 5000 cells were used in total, and GFP+ HDFs and MSCs were cocultured in ratios of 2:1 and 1:1 for 1 day. During the fabrication and culture of HUVECs spheroids, EGM-2MV medium (Lonza) was used.

Field-emission SEM (FEI Nova NanoSEM 630) was used to investigate the surface topography of fabricated spheroids and dissociated electrocytes (see the Supplementary Materials for dissociation of electrocytes). Spheroids were harvested after 2 days of culture. Spheroids and electrocytes were fixed in 4% paraformaldehyde (Sigma-Aldrich) overnight; samples were then carefully washed in phosphate-buffered saline (PBS) and dehydrated using graded ethanol solutions (25 to 100%). To ensure complete removal of water, samples were further dried in a critical point dryer (CPD300, Leica EM, Wetzlar, Germany). On complete dehydration, they were sputter-coated with iridium (Leica) and imaged at an accelerating voltage of 3 to 5 keV.

A total of 1000 2-day cultured spheroids of each type (with ~2500 cells per spheroid) were collected and homogenized in 100 l of distilled water. Then, 100 l of cell homogenate was transferred to a 2-ml pressure-tight vial, added with 100 l of 12 M hydrochloric acid, and hydrolyzed at 120C for 3 hours. The total collagen amount per spheroid type was quantified using a hydroxyproline colorimetric assay kit (BioVision Inc., CA) according to the manufacturers instructions. Collagen amount expressed by each spheroid type was determined using a PowerWave X-340 spectrophotometer (BioTek, Winooski, VT) at 560 nm, and the results were normalized to the collagen amount expressed by HUVEC spheroids at day 2. Experiments were repeated four times.

Bioprinting of spheroids was used with a MakerBot Replicator 1 3D printer (MakerBot, NY). The extrusion head was removed, and a holder for a pipette and two microvalve heads was 3D-printed using an Ultimaker 2 (Ultimaker) 3D printer. To control the 3D motion stage, a smoothie board (Uberclock, OR) was integrated. The reader is referred to the Supplementary Materials for the details on the construction of the AAB platform.

For fabrication of support constructs, microvalves (INKX0517500A, Lee Company, Bashville, TN) with 250-m nozzles (INZA3100914K, Lee Company) were integrated on the bioprinter head. To operate microvalves, a control board (IECX0501350A, Lee Company) was used, which was controlled using Arduino Uno (Arduino, Italy). To cross-link sodium alginate, a portable ultrasonic humidifier (CZHD20, Comfort Zone, China) was used to generate the aerosol form of CaCl2. Details about the bioprinter setupincluding the computer aided design model (fig. S1D), block diagram (fig. S1E), and computer interface (fig. S20)can be found in the Supplementary Materials.

Spheroids were collected into a petri dish from U-bottom 96-well plates, and then, their surface tension was measured using a micropipette aspiration technique, as explained in our recent work (8). Aspirated spheroids were monitored via an STC-MC33USB monochromatic camera (Sentech, Japan) equipped with 1-61448 and 1-61449 adaptor tubes (Navitar, Rochester, NY).

Spheroids fixed in 4% paraformaldehyde (Sigma-Aldrich) and rinsed in Dulbeccos PBS (DPBS) were stained with NucBlue ReadyProbes reagent (Life Technologies) to visualize the cell nuclei (Fig. 3, A3 and A4); actin cytoskeletal fibers were stained with ActinGreen 488 ReadyProbes reagent according to the manufacturers instructions. Imaging and 3D reconstruction of a heterogeneous pyramid structure (Fig. 4A) was performed using a Zeiss confocal microscope (LSM 880, Carl Zeiss AG, Oberkochen, Germany) using a 5 lens. The 3D reconstruction was obtained using Zen blue software (Carl Zeiss AG). A diamond structure (Fig. 4D) was first imaged through Zeiss Axiozoom (Carl Zeiss AG, Oberkochen, Germany) to capture the entire 3D structure and then further imaged on a confocal microscope (Olympus FV1000, Olympus America Inc., Center Valley, PA) to closely image the DAPI (4,6-diamidino-2-phenylindole), F-actin, and CD31 staining.

Spheroids were removed from the U-bottom well plates and subjected to the bioprinting process. Spheroids directly taken from plates were used as a positive control group. Viability was assessed using a LIVE/DEAD viability assay kit (Life Technologies, Grand Island, NY). Briefly, spheroids were washed twice in DPBS and then placed in the dye solution consisting of 1 M calcein acetoxymethyl and 1.6 M ethidium homodimer-1 in PBS. Live cells were able to take up and retain the calcein dye, resulting in bright green fluorescence of their cytoplasm. The ethidium homodimer could only enter dead cells where it binds to nucleic acids, producing a bright red fluorescence. Spheroids were imaged at 20-m z-stack step size on the Olympus FV1000 confocal microscope with a 60-m aperture setting resulting in approximately five to seven images per spheroid. Each image was then analyzed using ImageJ software (National Institutes of Health, USA).

Spheroids made of 3T3 cells were collected from U-bottom 96-well plates and then washed with DPBS twice. CellTracker Orange CMTMR [5-(and-6)-(((4-chloromethyl)benzoyl)amino) tetramethylrhodamine] (Thermo Fisher Scientific) and CellTracker Green CMFDA (5-chloromethylfluorescein diacetate) (Thermo Fisher Scientific, MA) were used according to the manufacturers instructions. Spheroids were bioprinted with close proximity, and then, images were captured at 0, 24, 48, and 72 hours using EVOS FL Cell Imaging System. The contact length and contact angle of two spheroids were measured every 4 hours up to 24 hours.

Images of sprouting GFP+ and tdTomato+ HUVEC spheroids at day 7 were taken on the Zeiss Axiozoom microscope at a magnification of 20 to capture the spheroids bioprinted at various distances. Images of sprouts at days 2 and 5 were taken using the EVOS FL Cell Imaging System. Sprouting behavior of spheroids was analyzed using AngioTool (41). To obtain the cross-sectional view of the capillary-like structures formed by GFP+ and tdTomato+ HUVEC spheroids at day 7, samples were imaged using a 40 oil lens on the Olympus FV1000 confocal microscope. For the study with GFP+ HDF/MSC coculture and HUVEC spheroids, samples were imaged on the EVOS microscope using fluorescent (4) channels at days 2 and 5. Images of those samples on day 7 were taken using fluorescent (16 and 40) and phase (16) channels by the Axiozoom microscope.

To induce osteogenic differentiation, MSC/HUVEC spheroids were bioprinted and cultured in two different strategies in a custom culture media made of 92% osteogenic differentiation media (Cell Applications Inc., San Diego, CA) and 8% HUVEC culture media. To confirm the morphology of bioprinted tissues undergoing osteogenic differentiation, tissues were sectioned and stained with RUNX2, CD31, F-actin, and DAPI. Cross-sectioned samples were washed three times with DPBS, fixed in 4% paraformaldehyde for 60 min, permeabilized in 0.2% Triton X-100 for 30 min, and blocked with 2.5% normal goat serum (NGS) for 60 min at room temperature. To visualize osteogenic and endothelial-specific genes, the samples were incubated with mouse anti-RUNX2 primary antibody (1:100 in 2.5% NGS) and rabbit anti-CD31 primary antibody (1:100 in 2.5% NGS) for 60 min; washed three times with DPBS; and incubated with goat anti-mouse Alexa Fluor 488 secondary antibody (Molecular Probes; 1:250 in 2.5% NGS) to label RUNX2, goat anti-rabbit Alexa Fluor 647 secondary antibody (Molecular Probes; 1:250 in 2.5% NGS) to label CD31, Alexa Fluor 568 phalloidin (Molecular Probes; 1:1000 in 2.5% NGS) to label filamentous actin, and DAPI (1:1000 in 2.5% NGS) to visualize cell nuclei for 60 min. The stained samples were washed three times with DPBS and imaged by an Olympus FV10i-LIV Confocal Laser Scanning Microscope (Olympus America Inc.) and analyzed using ImageJ software. In addition to sectioned samples, bioprinted tissues were also stained, as a whole-mount sample, as explained above, and fluorescent images were taken on the Zeiss Axiozoom microscope.

To confirm the calcium deposition, cross-sectioned samples were fixed in 4% paraformaldehyde, washed three times with distilled water, and incubated with 2% Alizarin red S stain solution for 30 min at room temperature. Stained samples were washed three times with distilled water and imaged using the EVOS microscope.

To quantify the intensity of RUNX2 and CD31, areas of interest on confocal images were selected using ImageJ. Fifty regions of interest were determined at the surface of the assembled tissue, spheroid-spheroid interface, and core of spheroids on fluorescent images. Each box was used for quantification of the fluorescence intensity. The intensity of RUNX2 and CD31 was normalized by the intensity of DAPI. A representative heat map was generated for the RUNX2/DAPI intensity.

Real-time polymerase chain reaction (PCR) was performed to quantify the gene expression levels of BSP, COL1, ALP, RUNX2, and CDH2. The primers of the measured mRNA genes were as follows: BSP (forward, AAC GAA GAA AGC GAA GCA GAA and reverse, TCT GCC TCT GTG CTG TTG), COL1 (forward, ATG ACT ATG AGT ATG GGG AAG CA and reverse, TGG GTC CCT CTG TTA CAC TTT), ALP (forward, AGC TGA ACA GGA ACA ACG TGA and reverse, CTT CAT GGT GCC CGT GGT C), RUNX2 (forward, GGT TAA TCT CCG CAG GTC ACT and reverse, CAC TGT GCT GAA GAG GCT GTT), CDH2 (forward, GAG CAG TGA GCC TGC AGA TTT T and reverse, TGC TCA GAA GAG AGT GGA AAG CT), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (forward, ATG GGG AAG GTG AAG GTC G and reverse, GGG GTC ATT GAT GGC AAC AAT A). Real-time PCR was analyzed by using SsoFast EvaGreen Supermix (Bio-Rad, USA), and all results were normalized using GAPDH.

All data were presented as means SD and analyzed by Minitab 17.3 (Minitab Inc., State College, PA, USA) using one-way analysis of variance (ANOVA) to test for significance when comparing the data. Post hoc Tukeys multiple-comparison test was used to determine the individual differences among the groups. Differences were considered significant at *P < 0.05, **P < 0.01, and ***P < 0.001. For directionality analysis, t test was used to compare the results between AOI and Other (where differences were considered significant at *P < 0.05, **P < 0.01, and ***P < 0.001), and ANOVA (with Tukeys multiple comparison test) was used to compare the results among different groups (where differences were considered significant at #P < 0.05, ##P < 0.01, and ###P < 0.001). Repeated-measures ANOVA (with Tukeys multiple-comparison test) was conducted to compare the results among different days of same groups, and differences were considered significant at *P < 0.05, **P < 0.01, and ***P < 0.001.

See original here:
Aspiration-assisted bioprinting for precise positioning of biologics - Science Advances

Despite Pro-Life Claims, Stem Cell Therapy Has Very Real Benefits and Should Be Accessible – Patheos

Stem cell research has been the subject of discussion and heated debate for many years. Much of the social and political drama surrounding stem cells is the result of misunderstanding what stem cells are, where they come from, and what they can do for those with injuries and diseases.

Working from a common set of facts is a great way to dispel controversy, however. Whether we fall into the pro-choice or pro-life camp, it is more than evident that supporting stem cell research, including the development of stem cell therapies, is very much a pro-life position to take.

Stem cells function essentially like raw materials for the body. Depending on instructions from the body (or researchers in laboratories), stem cells can become many other types of cells with specialized functions.

The daughters of stem cells either become new stem cells (self-renewal) or they become more specialized cells for use in specific areas of the body (differentiation). These specialized cells include brain cells, heart muscle cells, bone cells, blood cells and others.

There are several reasons why stem cells are the focus of some of the most important medical science research today:

This last avenue of medical research stem cell therapies is the most consequential as well as the most controversial, depending on your point of view. Understanding stem cell therapy and its divisiveness requires understanding where stem cells come from in medical research and why they have considerable palliative potential.

Stem cells come from one of these three sources:

Embryonic stem cells are the most controversial as well as the most important type of stem cells right now. Thanks to a low-information electorate and gross misinformation from within the government, embryonic stem cells remain mired in needless debate.

Despite the rhetoric, these cells arent harvested from slain newborns. Instead, they are carefully gathered from blastocysts. Blastocysts are three-to-five-day-old embryos comprised of around 150 cells. According to some religious-political arguments, blastocysts are potential human beings, and therefore deserve legal protection.

Embryonic stem cells are the most valuable in medical research because they are fully pluripotent, which means they are versatile enough to become any type of cell the body requires to heal or repair itself.

Adults have limited numbers of stem cells in a variety of bodily tissues, including fat and bone marrow. Unlike pluripotent embryonic stem cells, adult stem cells have more limits on the types of cells they can become.

However, medical researchers keep uncovering evidence that adult stem cells may be more pliable than they originally believed. There is reason to believe cells from adult bone marrow may eventually help patients overcome heart disease and neurological problems. However, adult stem cells are more likely than embryonic stem cells to show abnormalities and environment-induced damage, including cell replication errors and toxins.

The newest efforts in stem cell research involve using genetic manipulation to turn adult stem cells into more versatile embryonic variants. This could help side-step the thorny abortion controversy, but its also not clear at present whether these altered stem cells may bring unforeseen side-effects when used in humans.

More research is required to fully understand the medical potential of perinatal stem cells. However, some scientists believe they may in time become a viable replacement for other types of stem cells. Perinatal stem cells come from amniotic fluid and umbilical cord blood.

Using a standard amniocentesis, doctors can extract umbilical cord mesenchymal stem cells, hematopoietic stem cells, amniotic membrane and fluid stem cells, amniotic epithelial cells and others.

Among other things, stem cell therapy is the next step forward for organ transplants. Instead of waiting on a transplant waiting list, patients may soon be able to have new organs grown from their very own stem cells.

Bone marrow transplants are one of the best-known examples of stem cell therapy. This is where doctors take bone marrow cells and induce them to become heart muscle cells.

Stem cell-based therapies hold significant promise across a wide range of medical conditions and diseases. With the right approach, stem cells show the potential to:

As the FDA notes, there is a lot of hype surrounding stem cell therapy. Much of it is warranted, but some of it deserves caution.

According to the FDA, stem cells have the potential to treat diseases or conditions for which few treatments exist. The FDA has a thorough investigational process for new stem cell-based treatments. This includes Investigational New Drug Applications (IND) and conducting animal testing.

However, the FDA notes that not every medical entity submits an IND when they bring a new stem cell therapy to market. It is vital that patients seek out only FDA-reviewed stem cell therapies and learn all they can about the potential risks, which include reactions at the administration site and even the growth of tumors.

The FDA submitted a paper, Clarifying Stem-Cell Therapys Benefits and Risks, to the New England Journal of Medicine in 2017. Its goal is to help patients fully understand what theyre getting themselves into.

For now, a great deal more research is required before we begin deploying stem cell therapies on a larger scale. The only FDA-approved stem cell therapies on the market today involve treating cancer in bone marrow and blood. Some clinics claim their therapy delivers miracle-like cures for everything from sports injuries to muscular dystrophy, but there just isnt enough evidence yet to take them at face value.

Unfortunately, the religious and political climate makes this evidence difficult to achieve. In some parts of the United States, the hostility toward stem cell researchers and medical practitioners has reached dangerous new levels.

Republicans in Ohio and Georgia want to make it illegal for doctors to perform routine procedures on ectopic pregnancies. This condition is life-threatening for the mother and involves the removal of a nonviable embryo from the fallopian tube.

These laws wouldnt just outlaw ectopic pregnancy surgery in the name of potential human life. It would, in fact, require women to undergo a reimplantation procedure after the ectopic pregnancy is corrected by a physician. If this procedure was actually medically possible, it would be dangerous and unnecessary. Thankfully, it doesnt exist outside the nightmarish imaginations of some of the more extreme Christian lawmakers and Planned Parenthood demonstrators.

Acquiring embryonic stem cells from ectopic pregnancies would seem to be the least controversial way to go about it. Unfortunately, even that small step toward medical progress sees itself hampered by reactionary politics.

No matter how theyre acquired, however, the 150 or so cells in blastocysts are packed with medical potential. Its clear that further exploration down this road will unlock unprecedented scientific progress. It will also, almost certainly, save many times more potential life than even the most outlandish estimates of what the achievement will cost us to achieve. Abortions today are rarer and safer than ever, and the vast majority occur within eight weeks of conception.

The medical community is poised for a revolution here, using these and other nonviable embryos and blastocysts. But realizing that potential requires, among other things, that we collectively make peace with modern medicine and family planning.

Read more:
Despite Pro-Life Claims, Stem Cell Therapy Has Very Real Benefits and Should Be Accessible - Patheos

Federal government investing nearly $7 million in stem cell research – inhalton.com

The federal government recently announced their intention to invest $6.9 million in stemcellresearch.

Stem cells are the building blocks of the body, and are responsible for growing and repairing tissue; they have the potential to treat a myriad of illnesses including heart disease--the leading cause of death inNorthAmerica.

Canada has been one of the leading countries when it comes to stem cell research, and Canadian researchers have brought stem cells from the lab into hospitals to savecountlesslives.

This funding will go towards nine translational projects and four clinical trials across the country aimed at providing new therapies and fostering continued growth in Canada's regenerativemedicinesector.

Two of the projects are being conducted by the Maisonneuve-Rosemont Hospital in Quebec; one trial involves testing a promising new protocol to make blood stem cell transplants available to more patients with severe leukemia, the other is a biotechnology partnership that is advancing a stem cell-based approach tovisionloss.

"When we invest in science, we invest in better, healthier lives for everyone," Navdeep Bains, Minister of Innovation, Science, and Industry, said in anewsrelease.

"Our government's support will help Canadian researchers further their ground-breaking work to tackle some of the most serious illnesses we face today. Congratulations to all of the recipients, and thank you for your work to keep Canada on the cutting edge of discovery and innovation,"hecontinued.

See the original post:
Federal government investing nearly $7 million in stem cell research - inhalton.com

Stem cell therapy used to treat severe cases – The Star Online

BEIJING: Chinese researchers are studying the use of stem cell technology in the treatment of people critically ill with the novel coronavirus disease (Covid-19), according to the Science and Technology Daily.

Four Covid-19 patients who received stem cell treatment while in a serious condition have been discharged from hospital after recovery, and the clinical trial of the therapy will be further expanded, Vice-Minister of Science and Technology Xu Nanping was quoted by the paper as saying.

Stem cells can self-renew or multiply while maintaining the potential to develop into other types of cells.

They can become cells of the blood, heart, lungs or other body parts.

Stem cells also have a strong secretory function, promoting the formation of new blood vessels, cell proliferation and differentiation and inhibiting inflammatory response, experts say.

Stem cell therapy has been used in the treatment of some infectious diseases and complications. For instance, it has been tried in treating H7N9 avian flu and showed good results.

According to the Ministry of Science and Technology, the Chinese Academy of Sciences has developed a new stem cell drug, CAStem, which has shown promising results in animal experiments.

The research team has applied for urgent assessment by the National Medical Products Administration.

Approvals by the ethics committee, and clinical observation and evaluation are in progress.

A research team from the fifth medical centre of the Chinese PLA General Hospital is cooperating with hospitals and institutions in Wuhan, the epicentre of the epidemic, and North Chinas Tianjin municipality to conduct clinical research on the safety and effectiveness of mesenchymal stem cell therapy in treating Covid-19 patients. China Daily/ANN

Read the original:
Stem cell therapy used to treat severe cases - The Star Online

NIH-funded i3 Center formed to advance cancer immunotherapy – Harvard Gazette

Steven Hodi Jr., the i3 Centers other PI, and director of Melanoma Center and the Center for Immuno-Oncology at Dana-Farber, and professor of medicine at Harvard Medical School (HMS), is leading the clinical cancer vaccine trial. He has been at the forefront of developing cancer immunotherapies using immune checkpoint inhibitors, a class of drugs able to re-activate tumor-destroying T cells that are muted in the tumor microenvironment. The funding for this center provides a unique opportunity to unite key investigators for translating fundamental advancements in immunology and biomedical engineering into highly synergistic approaches to improve the treatments for cancer patients, said Hod

Using both in vivo and ex vivo biomaterials-based approaches, the i3 Center aims to boost tumor-specific activities of cytotoxic T cells, by boosting different stages of the normal process by which T cells develop, and acquire anti-cancer activity. T cells normal development starts in the bone marrow where hematopoietic stem cells generate T cell progenitor cells. These migrate to the thymus to differentiate into nave T cells, which then travel further to lymph nodes. There, they encounter cancer-derived antigens presented to them by specialized antigen-presenting cells (APCs) that can activate T cells to recognize and eliminate cancer cells.

In relation to adoptive T cell therapies in which T cells are given to patients to fight their cancers, one team at the i3 Center will be led by Dana-Farber researchers Catherine J. Wu and Jerome Ritz, who along with Mooney, will develop and test biomaterials that can better mimic normal APCs in activating and directing the function of patient-derived T cells outside the human body, prior to their transplantation. Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies, and Ritz is executive director of the Connell and OReilly Families Cell Manipulation Core Facility at Dana-Farber.

We need to make efforts to enhance the ability of theimmune systemto recognizetumor cells. One directionmylaboratoryis taking makes use of innovative biomaterialsto help us to efficiently expandpolyclonaltumor-specificfunctionally-effectiveT cellsex vivoin a way that can be readily translated to theclinical setting. In our studies, we are currently focusing on melanoma and acute myeloid leukemia, said Wu, whose research interests include understanding the basis of effective human anti-tumor responses, including the identification and targeting of the tumor-specific antigens.

A second project explores the use of DNA origami, biocompatible nanostructures composed of DNA, to create cancer vaccines. DNA origami could provide significant advantages in presenting tumor-specific antigens and immune-enhancing adjuvants to APCs because the concentrations, ratios, and geometries of all components can be modulated with nano-scale precision to determine configurations that are more effective than other vaccination strategies. The project will be run by Wyss Institute Core Faculty member William Shih, Derin Keskin, lead immunologist at Dana-Farbers Translational Immunogenomics Lab, and Mooney.

In a third project, David Scadden, professor at Harvards Department of Stem Cell and Regenerative Biology, will collaborate with Mooney to build on their previous work. They will engineer biomaterials that recreate key features of the normal hematopoietic stem cell niche in the bone marrow. Such implantable biomaterials could help rapidly amplify T cell progenitor cells, and enhance T cell-mediated anti-cancer immunity. Scadden also is the Gerald and Darlene Jordan Professor of Medicine at Harvard University, and co-director of the Harvard Stem Cell Institute.

The i3 Centers investigators anticipate that it will stimulate additional cross-disciplinary concepts and research, due to the culture of continuous interactions, sharing of findings, data and samples between all investigators, as well strong biostatistical expertise provided by Donna Neuberg, a senior biostatistician broadly involved with exploring immune-modulating cancer interventions at the Dana-Farber.

This new i3 Center for cancer immunotherapy innovation really embodies how the Wyss Institute with its unparalleled capabilities in bioengineering and serving as a site for multidisciplinary collaboration, and can liaise with clinicians and researchers at our collaborating institutions to confront major medical problems and bring about transformative change, said Wyss Founding Director Donald Ingber. He is also theJudah Folkman Professor of Vascular Biologyat HMS and the Vascular Biology Program at Boston Childrens Hospital, and Professor of Bioengineering at SEAS.

Continued here:
NIH-funded i3 Center formed to advance cancer immunotherapy - Harvard Gazette

Stem Cell Therapy Market 2020 Global Market Size, Analysis, Share, Research, Business Growth and Forecast to 2027 Coherent Market Insights – Bandera…

Coherent Market Insights published informative report on Global Stem Cell Therapy Market presents market size, historical breakdown data (20142019) and forecast (20202027). The report encompass insightful data on the main sectors of the global market. The report also evaluates the size, share, and growth rate of the businesses by conducting detailed analysis of the contribution of leading market players to the global industry.

The report emphasized competitive structure, segmentation, leading competitors, and industry environment. The report investigates Stem Cell Therapy market dynamics, including growth drivers, restraints, potential opportunities, threats, challenges, and other market trends.

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint

Key players analyzed in the Stem Cell Therapy market study:

Osiris Therapeutics, Inc. Novartis AG, GlaxoSmithKline Plc., MEDIPOST Co., Ltd., Anterogen Co., Ltd. Pharmicell Co., Ltd. Holostem Terapie Avanzate S.r.l. JCR Pharmaceuticals Co., Ltd. NuVasive, Inc. RTI Surgical, Inc., and Fibrocell Science, Inc.

This Stem Cell Therapy report is very reliable as all the data and the information regarding the fnb industry is collected via genuine sources such as websites, journals, annual reports of the companies, and magazines. This global market research report is likely to show a considerable growth of market in percentage during the forecast period. Key insights of the report are complete and distinct analysis of the market drivers and restraints, major market players involved in this industry, detailed analysis of the market segmentation and competitive analysis of the key players involved.

Our competitor profiling includes evaluation of distribution channels and products and services offered by and financial performance of companies operating in the global Stem Cell Therapy market. We also provide Porters Five Forces, PESTLE, and SWOT analysis to assess competitive threat and examine other aspects of the global Stem Cell Therapy market. The report offers strategic recommendations, competitor benchmarking for performance measurement, and analysis of partnership, merger, and acquisition targets and industry best practices. It also provides analysis of profitability and cost across the industry value chain.

Competitive Rivalry-: The Stem Cell Therapy report incorporates the detailed analysis of the leading organizations and their thought process and what are the methodologies they are adopting to maintain their brand image in this market. The report aides the new bees to understand the level of competition that they need to fight for to strengthen their roots in this competitive market.

Principal Research:

The research team works with industry experts from the Global Stem Cell Therapy industry including the management organizations, processing organizations, value chain analytics by service providers of the Stem Cell Therapy market.

Subordinate Research:

In the Secondary research vital information about the Stem Cell Therapy industries value chain, total pool of key players, and application areas. Market separation is done as per the industrial drifts to the deepest level, terrestrial markets and key developments from both market place and technology-oriented viewpoints.

Various features and important queries have been answered in top-notch report

Competitors

In this section, various Stem Cell Therapy industry leading players are studied with respect to their company profile, product portfolio, capacity, price, cost, and revenue.

Sales and Revenue Analysis

Both, sales and revenue are studied for the different regions of the Stem Cell Therapy Market. Another major aspect, price, which plays an important part in the revenue generation, is also assessed in this section for the various regions.

Market Dynamics

The analysts explore critical influence factors, market drivers, challenges, risk factors, opportunities, and market trends in this section.

Application Usage

The section provides up-to-date information on the customer experience which can help identify the problems as well as detailed errors in the products. Through these findings, you will be able to provide solutions to it.

Why Purchase from Coherent Market Insights?

Data gathered by interviewing product development managers, CEOs, marketing executives, and other individuals affiliated to the Stem Cell Therapy market

Round the clock customer service to address client queries

Systematic, efficient, and result-oriented approach towards curating market reports

We offer business intelligence reports for a range of industrial verticals

Tailor-made reports available to fulfil the requirements of our clients

The report could be customized according to the clients specific research requirements. No additional cost will be required to pay for limited additional research.

In this study, the years considered to estimate the market size of 2020-2027 Stem Cell TherapyMarket are as follows:History Year: 2014-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2027

Contact Us:Name: Mr.ShahPhone: US +12067016702 / UK +4402081334027Email: sales@coherentmarketinsights.comVisit our Blog: https://hospitalhealthcareblog.wordpress.com/

Link:
Stem Cell Therapy Market 2020 Global Market Size, Analysis, Share, Research, Business Growth and Forecast to 2027 Coherent Market Insights - Bandera...

Increasing Demand of Cancer Stem Cell Therapy Market by 2020-2026 with Top Key Players like #VALUE! – News Times

Cancer Stem Cell Therapy Market research report has been published by A2Z Market Research to give desired insights to drive the growth of businesses. The report has been intelligently framed with the process of gathering and calculating numerical data regarding services and products. The report is inclusive of the prominent industry drivers and provides an accurate analysis of the key growth trends and market outlook in the years to come in addition to the competitive hierarchy of this sphere.

Get Sample copy of this Report @: http://www.a2zmarketresearch.com/sample?reportId=194432

Some of the Top Companies covered in this Report includes: AVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems.

The global Cancer Stem Cell Therapy market is analyzed in terms of its competitive landscape. For this, the report encapsulates data on each of the key players in the market according to their current company profile, gross margins, sale price, sales revenue, sales volume, product specifications along with pictures, and the latest contact information. The reports conclusion leads into the overall scope of the global market with respect to feasibility of investments in various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the global Cancer Stem Cell Therapy market in the near future.

The report summarized the high revenue that has been generated across locations like, North America, Japan, Europe, Asia, and India along with the facts and figures of Cancer Stem Cell Therapy market. It focuses on the major points, which are necessary to make positive impacts on the market policies, international transactions, speculation, and supply demand in the global market.

Global Cancer Stem Cell Therapy Market Detail Segmentation:

Segmentation by Type:

Segmentation by Application:

For More Information, [emailprotected]: http://www.a2zmarketresearch.com/enquiry?reportId=194432

Impressive insights of Global Cancer Stem Cell Therapy Market Research report:

Table of Contents

Global Cancer Stem Cell Therapy Market Research Report 2020 2026

Chapter 1 Cancer Stem Cell Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Cancer Stem Cell Therapy Market Forecast

Buy Complete Report Only @ 2800 USD: http://www.a2zmarketresearch.com/buy?reportId=194432

If you have any special requirements, please let us know and we will offer you the report as you want.

Originally posted here:
Increasing Demand of Cancer Stem Cell Therapy Market by 2020-2026 with Top Key Players like #VALUE! - News Times

Stem Cell Antibody Market Report by Manufacturers, Regions, Type and Application Forecast 2019 2026 – News Times

In the latest report on Stem Cell Antibody Market, added by UpMarketResearch.com, a concise analysis on the recent industry trends is covered. The report further includes statistics, market forecasts and revenue estimations that in addition highlights its status in the competitive domain as well as expansion trends adopted by major industry players.

The report is a detailed study on the Stem Cell Antibody Market with details regarding an in-depth assessment of the industry vertical. The evaluation is performed taking into consideration a dual perspective of consumption and production.

Request a sample Report of Stem Cell Antibody Market at: https://www.upmarketresearch.com/home/requested_sample/51767

Speaking of the production category, the report provides details regarding the product renumeration, manufacturing of the product and the gross margins of the firms manufacturing the products. With regards to the consumption, the study elaborates about the product consumption value and the product consumption volume along the status of import as well as export of the products.

A brief of the regional landscape:

Regional segmentation: North America, Europe, Asia Pacific, Middle East & Africa, Latin America.

What is the main objective of this section?

The report provides an overview of the regional segment of this industry.

Important details covered in the report:

An outline of the product spectrum:

Product segmentation:

Primary AntibodiesSecondary Antibodies

What is the main objective of this section?

The report provides an overview of the product reach.

Providing an overview of the report:

Data related to the application terrain:

Application segmentation:

ProteomicsDrug DevelopmentGenomics

What is the main objective of this section?

The study states details regarding the classification of the application spectrum.

Ask for Discount on Stem Cell Antibody Market Report at: https://www.upmarketresearch.com/home/request_for_discount/51767

Assessment of the application-based segment of the Stem Cell Antibody market:

An outline of the competitive reach:

Competitive segmentation:

Thermo Fisher Scientific Inc. (U.S.)Merck Group (Germany) Abcam plc (U.K.)Becton Dickinson and Company (U.S.)Bio-Rad Laboratories Inc. (U.S.)Cell Signaling Technology Inc. (U.S.)Agilent Technologies Inc. (U.S.)F. Hoffmann-La Roche Ltd (Switzerland)Danaher Corporation (U.S.)GenScript (U.S.) PerkinElmer Inc. (U.S.)Lonza (Switzerland) and BioLegend Inc. (U.S.)

What is the main objective of this section?

The report provides details regarding the competitive spectrum of the Stem Cell Antibody market.

Details from the report:

Information related to the growth margins of the firms, manufacturing expenses, renumeration and product costs are provided in the report.

The research report offers data related to the level to which the industry has been evaluated. Data with respect to analysis of the possibility of new investment projects undertaken as well as the research conclusions are inculcated in the report.

For More Information on this report, Request Inquiry At https://www.upmarketresearch.com/home/enquiry_before_buying/51767

Some of the Major Highlights of TOC covers:

Development Trend of Analysis of Stem Cell Antibody Market

Marketing Channel

Market Dynamics

Methodology/Research Approach

Purchase of This Report:https://www.upmarketresearch.com/buy/stem-cell-antibody-market

About UpMarketResearch:Up Market Research (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info UpMarketResearchName Alex MathewsEmail [emailprotected]Organization UpMarketResearchAddress 500 East E Street, Ontario, CA 91764, United States.

Read more:
Stem Cell Antibody Market Report by Manufacturers, Regions, Type and Application Forecast 2019 2026 - News Times

Exploiting Immunobiology To Treat Severe Autoimmune and Inflammatory Disorders – Technology Networks

Technology Networksrecently had the pleasureof speaking with Bruce Steel, CEOEquillium, Inc. to learn more about how they are leveraging their comprehensive understanding of immunobiology to develop novel treatments for inflammatory and autoimmune disorders.Bruce provides insight on the various indications the company is currently developing treatments for, elaborates on the clinical progress of their initial product candidate EQ001 (itolizumab), and explains the role CD6 plays in autoimmunity and how it can be targeted therapeutically.

Laura Lansdowne (LL): How can immunobiology be harnessed to develop therapeutics?Bruce Steel (BS): The role of the immune system is to defend the body against foreign organisms and cells, including cancerous cells, and in doing so, it must distinguish accurately between self- and non-self-entities a process called tolerance. Autoimmunity is an immune response directed against the bodys own healthy cells and tissues and is the underlying process in many inflammatory diseases. Autoimmunity results from a loss of tolerance caused in part by an imbalance in the relationship between effector T cells and regulatory T cells. Therefore, developing therapeutics, such as EQ001 (itolizumab), that target these critical regulators of immune activation pathways has the potential dramatically improve the lives of patients with severe autoimmune and inflammatory disorders.LL: What indications are you currently developing treatments for?BS: We select target indications based on three primary criteria: strong scientific rationale for why itolizumab has potential to be a best-in-class therapeutic approach, areas of high unmet medical need where there are little or no treatments available today, and indications where we believe there is an attractive future commercial opportunity. Today we have ongoing clinical trials with itolizumab in acute graft-versus-host disease (GVHD), uncontrolled asthma and lupus/lupus nephritis.

While these three indications are our initial areas of focus, we believe itolizumab has the potential to be developed in other areas such as transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders.We licensed itolizumab from our partner Biocon Limited who developed the drug and received regulatory approval in India for the treatment of psoriasis.LL: Can you tell us more about the mechanism of your drug candidate EQ001 (itolizumab)?BS: Itolizumab is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway, which plays a central role in modulating the activity and trafficking of effector T cells that drive a number of immune-inflammatory diseases.LL: What role does CD6 play in autoimmunity?BS: CD6 is a novel co-stimulatory receptor that uniquely modulates T cell activity and trafficking. It is a key checkpoint in regulating effector T cells that are central to autoimmune responses. CD6 binds activated leukocyte cell adhesion molecule (ALCAM). ALCAM is expressed on both antigen-presenting cells and tissue including the skin, gut, lung and kidney.In preclinical studies, blockade of CD6 with itolizumab leads to reduction in effector T cell activation and proliferation. Additionally, inhibiting the binding of ALCAM to CD6 with itolizumab modulates lymphocyte trafficking and reduces effector T cell infiltration into inflamed tissues.

Our work with CD6 builds upon the research conducted from researchers at the Dana-Farber Cancer Institute, our partner Biocon, and other leading academic centers. Today there are numerous peer reviewed publications related to the novel CD6 checkpoint receptor and targeting the CD6-ALCAM pathway.LL: Can you elaborate on the clinical progress of itolizumab?BS: Itolizumab is currently being studied in three different indications: acute graft-versus-host disease (aGVHD), uncontrolled moderate to severe asthma and lupus/lupus nephritis. This is an important catalyst year for Equillium as we expect initial data from all three programs in 2H 2020.

Each of these studies will allow us to understand the safety of itolizumab in these different disease areas and understand what potential dose we will carry forward. This is important as we consider making a larger investment in Phase II studies to advance the program.Bruce Steel was speaking with Laura Elizabeth Lansdowne, Senior Science Writer for Technology Networks.

Original post:
Exploiting Immunobiology To Treat Severe Autoimmune and Inflammatory Disorders - Technology Networks